Literature DB >> 7766468

[Scimitar syndrome: series of 12 cases].

J Lluna González1, J E Barrios Fontoba, T Cavalle Garrido, C Gutiérrez San Roman, P Malo Concepción, J I Carrasco Moreno, J R Mínguez Esteban, E Tomás Collado, R Aparici Izquierdo.   

Abstract

Our experience in 12 cases of pediatric patients with scimitar syndrome is reported. Except for one, all of them presented cardiac or respiratory manifestations. The symptomatology was related to associated defects (3 atrial septal defects and 1 multiple peripheric pulmonary stenosis), degree of pulmonary hypoplasia, size of the right to left shunt and pulmonary hypertension. 3 patients underwent surgical treatment. One of them died during operation and the other two have had a good evolution. Nine patients with later respiratory manifestations have improved their condition progressively without surgical intervention. Therapeutic approach for patients with scimitar syndrome, respiratory manifestations and onset beyond the neonatal period, should be conservative.

Entities:  

Mesh:

Year:  1995        PMID: 7766468

Source DB:  PubMed          Journal:  Cir Pediatr        ISSN: 0214-1221


  4 in total

1.  Unique technique of surgery in an unusual variety of Scimitar syndrome: a case report.

Authors:  Julia Nuebel; Katarzyna Januszewska; Markus Loeff; Daniel Theisen; Edward Malec; Robert Dalla-Pozza
Journal:  J Cardiothorac Surg       Date:  2010-03-25       Impact factor: 1.637

2.  Scimitar syndrome.

Authors:  Muktachand L Rokade; R V Rananavare; Devdas S Shetty; Shenaz Saifi
Journal:  Indian J Pediatr       Date:  2005-03       Impact factor: 1.967

3.  Scimitar syndrome and evolution of managements.

Authors:  Mahdi Kahrom; Hadi Kahrom
Journal:  Pan Afr Med J       Date:  2009-12-17

4.  Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer.

Authors:  Wanting Shao; Christina Kuhn; Doris Mayr; Nina Ditsch; Magdalena Kailuwait; Verena Wolf; Nadia Harbeck; Sven Mahner; Udo Jeschke; Vincent Cavaillès; Sophie Sixou
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-03       Impact factor: 4.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.